Bafna Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the Quarter ended March 31, 2026.
BAFNAPH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Bafna Pharmaceuticals has filed a routine regulatory compliance certificate confirming proper handling of share dematerialization for Q4 FY2025-26 (January-March 2026). The company's Registrar and Share Transfer Agent, Cameo Corporate Services Limited, certified that all securities received from depository participants for dematerialization were confirmed, listed on stock exchanges, and the corresponding physical share certificates were cancelled. This is a mandatory quarterly filing under SEBI Regulation 74(5) to ensure proper processing of dematerialization requests.
No direct impact on stock price or shareholder value. This is a standard compliance filing confirming proper administrative processing of share certificates and has no bearing on the company's financial performance or operations.